FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
	OMB Number:	3235-0287								
l	Estimated average burd	en								
	hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  SATO VICKI L  (Last) (First) (Middle)  C/O VERTEX PHARMACEUTICALS INCORPORATED  130 WAVERLY STREET						ERT		PHA		or Trad IACE		ymbol <mark>ICALS</mark>	(Ch	eck all applic Directo Officer	ationship of Reporting k all applicable) Director Officer (give title below)		on(s) to Iss 10% Ov Other (s below)	vner		
						Date of /12/2		est Trar	nsact	tion (Mo	onth/E	ay/Year)			President					
130 WAVERLI STREET						4. If Amendment, Date of Original Filed (Month/Day/Year)										ndividual or Joint/Group Filing (Check Applicable e)				
(Street) CAMBRIDGE MA 02139					_											Form f	Form filed by One Reporting Person  Form filed by More than One Reporting  Person			
(City)	(S	State)	(Zip)																	
		Tab	le I - Noi	n-Deriv	vativ	e Se	curit	ies A	cqu	ired,	Dis	osed o	f, o	r Ben	eficial	ly Owned				
				Date	2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)				Benefici Owned I	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
									Ī	Code	v	Amount		(A) or (D)	Price		saction(s) c. 3 and 4)			(Instr. 4)
Common	Stock			11/1	11/12/2003					M		3,800	) A	A	\$7.8	3 100	100,408		D	
Common	Common Stock 11/12					2/2003				<b>S</b> <sup>(1)</sup>		3,800	0	D	\$8.16	96,608		D		
Common	Stock															7,	7,079 I 401(k)			
		•	Table II -									sed of, onvertil				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	4. Transa Code ( 8)		of E		Exp	Date Exe Diration I Dinth/Day	Date		7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s llly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Cod	Code	v			Dat Exe			expiration ate			Amount or Number of Shares					
Stock	\$7.88	11/12/2003			M			3,800	03/3	31/1994 <sup>(</sup>	(2)	1/30/2003	Con	nmon	3,800	\$8.16	1,225,0	09	D	

## **Explanation of Responses:**

- 1. Transaction made pursuant to Dr. Sato's company approved trading plan established under Rule 10b5-1.
- 2. Right to buy under 1991 Stock and Option Plan, vesting in 20 equal quarterly installments from 12/01/1993.

## Remarks:

Valerie L. Andrews, Attorney-In-Fact

11/13/2003

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.